A subanalysis of data from the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial reported that renal dysfunction was associated with a lower TTR of VKA during the administration period [5]. The gene discussed is F10; the disease is atrial fibrillation.